A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel
Clinical trial NCT04252768 · WITHDRAWN
Trial details
- NCT number
- NCT04252768
- Sponsor
- Immutep S.A.S.
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-01
- Primary completion
- 2025-06-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.